Weight Loss & Metabolic

GLP-1 and multi-receptor agonists studied for obesity and glycemic control.

Mounjaro, Zepbound

A dual GIP/GLP-1 receptor agonist producing the largest weight reduction of any currently approved incretin therapy.

A triple GLP-1/GIP/glucagon receptor agonist in late-stage trials, with the highest reported weight reduction to date in obesity studies.

A modified fragment of human growth hormone (176-191) marketed for fat loss, with human trials that failed to separate from placebo.